The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study
Open accessAbstract
OBJECTIVE: To compare the effectiveness of discontinuing treatment with amoxicillin after three days or eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment. DESIGN: Randomised, double blind, placebo controlled non-inferiority trial. SETTING: Nine secondary and tertiary care hospitals in the Netherlands. PARTICIPANTS: Adults with mild to moderate-severe community acquired pneumonia (pneumonia severity index score < or = 110). INTERVENTIONS: Patients who had substantially improved after three days' treatment with intravenous amoxicillin were randomly assigned to oral amoxicillin (n = 63) or placebo (n = 56) three times daily for five days. MAIN OUTCOME MEASURES: The primary outcome measure was the clinical success rate at day 10. Secondary outcome measures were the clinical success rate at day 28, symptom resolution, radiological success rates at days 10 and 28, and adverse events. RESULTS: Baseline characteristics were comparable, with the exception of symptom severity, which was worse in the three day treatment group. In the three day and eight day treatment groups the clinical success rate at day 10 was 93% for both (difference 0.1%, 95% confidence interval--9% to 10%) and at day 28 was 90% compared with 88% (difference 2.0%,--9% to 15%). Both groups had similar resolution of symptoms. Radiological success rates were 86% compared with 83% at day 10 (difference 3%,--10% to 16%) and 86% compared with 79% at day 28 (difference 6%,--7% to 20%). Six patients (11%) in the placebo group and 13 patients (21%) in the active treatment group reported adverse events (P = 0.1). CONCLUSIONS: Discontinuing amoxicillin treatment after three days is not inferior to discontinuing it after eight days in adults admitted to hospital with mild to moderate-severe community acquired pneumonia who substantially improved after an initial three days' treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Outpatient antibiotic use in Europe and association with resistance: a cross-national database study
Goossens, H., Ferech, M., Vander Stichele, R., & Elseviers, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17907-0 · Cited by 3,359
Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults
Bartlett, J. G., Dowell, S. F., Mandell, L. A., File, T. M., Musher, D. M., & Fine, M. J. (2000) · Clinical Infectious Diseases · doi:10.1086/313954 · Cited by 2,286
Niederman, M. S., Mandell, L. A., Anzueto, A., Bass, J. B., Broughton, W. A., Campbell, G. D., Dean, N., File, T., Fine, M. J., Gross, P. A., et al. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.7.at1010 · Cited by 2,150
Seppälä, H., Klaukka, T., Vuopio-Varkila, J., Muotiala, A., Helenius, H., Lager, K., & Huovinen, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370701 · Cited by 1,206
The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe
Bronzwaer, S. L. A. M., Cars, O., Buchholz, U., Mölstad, S., Goettsch, W., Veldhuijzen, I. K., Kool, J. L., Sprenger, M. J. W., Degener, J. E., & System, P. I. T. E. A. R. S. (2002) · Emerging Infectious Diseases · doi:10.3201/eid0803.010192 · Cited by 690
Guillemot, D., Carbon, C., Balkau, B., Geslin, P., Lecoeur, H., Vauzelle-Kervroëdan, F., Bouvenot, G., & Eschwége, E. (1998) · JAMA · doi:10.1001/jama.279.5.365 · Cited by 545
Felmingham, D., & Grüneberg, R. N. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.191 · Cited by 368
High‐Dose, Short‐Course Levofloxacin for Community‐Acquired Pneumonia: A New Treatment Paradigm
Dunbar, L. M., Wunderink, R. G., Habib, M. P., Smith, L. G., Tennenberg, A. M., Khashab, M. M., Wiesinger, B. A., Xiang, J. X., Zadeikis, N., & Kahn, J. B. (2003) · Clinical Infectious Diseases · doi:10.1086/377539 · Cited by 335
BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.
(2001) · PubMed · doi:10.1136/thorax.56.suppl_4.iv1 · Cited by 272
Schrag, S. J., Peña, C., Fernández, J., Sánchez, J., Gómez, V., Pérez, E., Feris, J. M., & Besser, R. E. (2001) · JAMA · doi:10.1001/jama.286.1.49 · Cited by 233
Finch, R., Schürmann, D., Collins, O., Kubin, R., McGivern, J., Bobbaers, H., Izquierdo, J. L., Nikolaides, P., Ogundare, F., Raz, R., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1746-1754.2002 · Cited by 181
PETITPRETZ, P., Arvis, P., Marel, M., Moita, J. J., & Urueta, J. (2001) · CHEST Journal · doi:10.1378/chest.119.1.185 · Cited by 131
O’Doherty, B., & Muller, O. (1998) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050201 · Cited by 106
Ortíz, G., Caballero‐Lopez, J., Friedland, I. R., Woods, G. L., Carides, A. D., & the Protocol 018 Ertapenem Community‐Acquired Pneumonia Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/339543 · Cited by 87
Hagberg, L., Torres, A. F., Rensburg, D. J. V., Leroy, B., Rangaraju, M., & Ruuth, E. (2002) · Infection · doi:10.1007/s15010-002-2096-z · Cited by 77
Bohte, R., Wout, J. W. V. ’., Lobatto, S., Alblas, A. B. V. O., Boekhout, M., Nauta, E. H., Hermans, J., & van den Broek, P. J. (1995) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf02310353 · Cited by 75
Hoepelman, I. M., Möllers, M. J., van Schie, M. H., Greefhorst, A. P. M., Schlösser, N. J. J., Damsté, E. J. S., van de Moosdijk, C. N. F., Dalinghaus, W. H., Eland, M. E., Mol, S., et al. (1998) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(97)00043-5 · Cited by 72
Regulating the use of antibiotics in the community
Carbon, C., & Bax, R. P. (1998) · BMJ · doi:10.1136/bmj.317.7159.663 · Cited by 71
Cited by
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
“In these trials, no difference was observed between 5 additional days of oral amoxicillin compared with placebo in patients who had clinically improved on 3 days of intravenous amoxicillin (194), or between 2 days of intravenous cefuroxime followed by 5 days versus 8 days of oral cefuroxime (195).”
BackgroundBarlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
Lim, W. S., Baudouin, S. V., George, R. C., Hill, A. T., Jamieson, C., Le Jeune, I., Macfarlane, J. T., Read, R. C., Roberts, H. J., Levy, M. L., et al. (2009) · Thorax · doi:10.1136/thx.2009.121434 · Cited by 1,420
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
Guidelines for the management of adult lower respiratory tract infections - Full version
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03672.x · Cited by 942
Metadata
- Authors
- Moussaoui, R. E., de Borgie, C. A. J. M., van den Broek, P., Hustinx, W. N., Bresser, P., van den Berk, G. E. L., Poley, J.-W., van den Berg, B., Krouwels, F. H., Bonten, M. J. M., Weenink, C., Bossuyt, P. M. M., Speelman, P., Opmeer, B. C., & Prins, J. M.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2006-06-08
- Volume
- 332
- Issue
- 7554
- Pages
- 1355
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2169983292
- Cited by
- 339
- References
- 21
- FWCI
- 14.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.